Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically\* or cytologically\* confirmed squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx, or larynx, including any of the following histologic variants:~  * Spindle cell carcinoma~ * Poorly differentiated keratin-positive carcinoma~ * Lymphoepithelioma NOTE: \*Biopsy or primary tumor and/or fine needle aspiration of the metastatic lymph node required~* Original or second primary tumor~  * Recurrent neck metastases with unknown primary allowed~* Locally recurrent disease~* Measurable disease~* Unresectable disease~  * Attempted surgical resection allowed provided surgery was performed ≥ 3 months ago, wound is completely healed, and there is no sign of carotid exposure~* Must have had prior radiotherapy for SCC of the head and neck with \> 75% of the present tumor volume in areas irradiated at doses ≥ 45 Gy but ≤ 75 Gy~  * Able to successfully re-irradiate the area of the gross tumor volume without exceeding lifetime spinal cord dose of 54 Gy as determined by physical examination and CT scan and/or MRI performed within the past 8 weeks~ * First recurrence occurred \> 6 months after completion of radiotherapy~    * More than 1 recurrence allowed provided the above criteria for first recurrence has been met~* No primary tumor of the nasopharynx or salivary gland~* No distant metastases by history or physical examination, chest CT scan, and CT scan or MRI of the tumor site~  * Patients with equivocal pulmonary nodules are eligible provided the nodules are \< 1 cm, can be safely biopsied, or are negative by positron emission tomography imaging~ * No circumferential tumor involvement of the carotid sheath by imaging unless prophylactic carotid stent is placed~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,800/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 8.0 g/dL (transfusion or other intervention allowed)~Hepatic~* AST or ALT \< 2 times upper limit of normal (ULN)~* Bilirubin \< 1.5 mg/dL~* No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects~Renal~* Creatinine clearance \> 50 mL/min~* Calcium \< 11.5 mg/dL~Cardiovascular~* No New York Heart Association class III or IV heart disease~* No other symptomatic or uncontrolled cardiac disease~Pulmonary~* No chronic obstructive pulmonary disease exacerbation~* No other respiratory illness requiring hospitalization within the past 6 months or that would preclude study therapy~Immunologic~* No AIDS~* No prior allergic reaction to E. coli-derived products~* No acute bacterial or fungal infection requiring IV antibiotics~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 30 days after completion of study treatment~* No other invasive malignancy within the past 3 years except nonmelanoma skin cancer, carcinoma in situ of the breast, oral cavity, or cervix~* No pre-existing peripheral sensory neuropathy \> grade 2~* No other severe active co-morbidity~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 6 months since prior chemotherapy~* No prior systemic chemotherapy for recurrent SCC of the head and neck~  * Prior neoadjuvant, adjuvant, and/or concurrent chemotherapy and radiotherapy for initial SCC of the head and neck allowed~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* See Chemotherapy~* At least 6 months since prior radiotherapy~Surgery~* See Disease Characteristics~Other~* Prior cyclooxygenase-2 inhibitor or retinoids for chemoprevention allowed~* At least 6 months since prior epidermal growth factor receptor (EGFR) inhibitors or other targeted agents~* No prior EGFR inhibitors or other targeted agents for recurrent SCC of the head and neck~* No concurrent cimetidine or allopurinol (for patients on arm II, regimen 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy and chemotherapy (Type: OTHER): Radiotherapy/paclitaxel/cisplatin/filgrastim
- Chemotherapy (Type: OTHER): Cisplatin/fluorouracil/paclitaxel/docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues